Analysis10k / Blog
EN한국어ES

Healthcare

24 articles in this industry.

LLY
Company Snapshot

Eli Lilly (LLY): What This Company Actually Does

A plain-English read of Eli Lilly's business model, built directly from its SEC filings — no hype, just where the money comes from.

2026-09-28
LLY
The Story

Eli Lilly's Last Three Years: A Company That Couldn't Keep Up With Its Own Success

How Mounjaro and Zepbound demand kept outrunning Eli Lilly's own guidance — and how the two moments that looked like trouble both turned into launching pads for the next raise.

2026-09-28
LLY
Reverse DCF

What LLY's Stock Price Is Really Betting On

Reverse-engineering the growth rate Eli Lilly's current share price already assumes — and why the answer swings wildly depending on which year's cash flow you use as a baseline.

2026-09-28
ABBV
Company Snapshot

AbbVie (ABBV): What This Company Actually Does

A plain-English read of AbbVie's business model, built directly from its SEC filings — no hype, just where the money comes from.

2026-09-27
ABBV
The Story

AbbVie's Last Three Years: 'Raising Guidance' While the Number Keeps Falling

How a CEO transition and a buying spree turned AbbVie's own guidance language into a puzzle worth decoding every quarter.

2026-09-27
ABBV
Reverse DCF

What ABBV's Stock Price Is Really Betting On

Reverse-engineering the growth rate AbbVie's current share price already assumes — and checking it against five years of shrinking free cash flow.

2026-09-27
PFE
Company Snapshot

Pfizer (PFE): What This Company Actually Does

A plain-English read of Pfizer's business — patented drugs and vaccines sold through a handful of wholesalers, paid for mostly by governments and insurers, not patients — built directly from its SEC filings.

2026-09-19
PFE
The Story

Pfizer's Story: A Guidance Cut, a Comeback, Then Two Shocks at Once

Pfizer slashed its own 2023 guidance in half and lost credibility, clawed it back with a conservative 2024 target it beat by a wide margin, then got hit by a failed obesity drug and a tariff shock in the same spring.

2026-09-19
PFE
Reverse DCF

What PFE's Stock Price Is Really Betting On

Reverse-engineering the free-cash-flow growth rate Pfizer's share price already assumes — and finding that the honest answer is Pfizer's own 5-year history is too distorted by COVID to judge it against.

2026-09-19
CVS
The Story

CVS Health's Rupture and Rebuild

In three quarters, CVS went from confidently reaffirming guidance to withdrawing it entirely and replacing its CEO — while its own filings quietly rewrote the language around exactly what went wrong.

2026-09-12
CVS
Reverse DCF

What CVS's Stock Price Is Really Betting On

Reverse-engineering the free-cash-flow growth rate CVS Health's share price already assumes — and comparing it with a company whose FCF has actually been shrinking for five years.

2026-09-12
JNJ
The Story

Johnson & Johnson's Last Three Years: Shed, Spend, and Recover

JNJ spun off its consumer business, then used the newfound freedom to spend $18 billion on acquisitions that deliberately sacrificed short-term profit — a bet that's now paying off in new-drug growth, right as the company prepares to shed another division.

2026-09-12
CVS
Company Snapshot

CVS Health (CVS): What This Company Actually Does

A plain-English read of CVS Health's business model — collecting insurance premiums, then selling the same customers their prescriptions through its own pharmacies — built directly from its SEC filings.

2026-09-12
MRK
Reverse DCF

What MRK's Stock Price Is Really Betting On

Reverse-engineering the free-cash-flow growth rate Merck's share price already assumes — and finding a moderately aggressive ask that has to hold up right through Keytruda's 2028 patent cliff.

2026-09-12
JNJ
Company Snapshot

Johnson & Johnson (JNJ): What This Company Actually Does

A plain-English read of Johnson & Johnson's business model — prescription drugs and hospital medical devices, sold through wholesalers and paid for by insurance — built directly from its SEC filings.

2026-09-12
CI
Company Snapshot

The Cigna Group (CI): What This Company Actually Does

A plain-English read of Cigna's business — selling health insurance and running Express Scripts, one of the country's largest prescription-drug middlemen — built directly from its SEC filings.

2026-09-12
CI
The Story

Cigna's Story: A Crisis, a Rebate-Free Pivot, and a 17-Year CEO Handoff

Cigna went from bragging about back-to-back guidance raises to admitting it fell 'short of our expectations' within a single year — then redesigned its core PBM business model and handed the CEO job to a 30-year insider.

2026-09-12
MRK
Company Snapshot

Merck (MRK): What This Company Actually Does

A plain-English read of Merck's business — the cancer immunotherapy Keytruda that alone drives nearly half of company revenue, plus vaccines and animal health — built directly from its SEC filings.

2026-09-12
JNJ
Reverse DCF

What JNJ's Stock Price Is Really Betting On

Reverse-engineering the free-cash-flow growth rate Johnson & Johnson's share price already assumes — and comparing it with a company whose FCF hasn't meaningfully grown in five years.

2026-09-12
MRK
The Story

Merck's Story: How an '$11 Billion by 2030' Promise Quietly Disappeared

For nearly three years, Merck insisted nothing had changed about Gardasil's $11 billion 2030 target. Then a Chinese distributor's inventory glut forced a formal withdrawal — in a single earnings call.

2026-09-12
CI
Reverse DCF

What CI's Stock Price Is Really Betting On

Reverse-engineering the free-cash-flow growth rate Cigna's share price already assumes — and finding one of the most pessimistic-looking market expectations this site has turned up.

2026-09-12
UNH
The Story

UnitedHealth's Last Three Years: From 'Balanced Growth' to a Guidance Collapse — and Back

How a confidently growing insurer blew through its own 2025 guidance twice, replaced its CEO, and has spent the months since trying to rebuild trust on a much lower bar.

2026-09-06
UNH
Reverse DCF

What UNH's Stock Price Is Really Betting On

Reverse-engineering the growth rate UnitedHealth's share price already assumes — and comparing it with the company's actual growth record, both before and after its 2025 crisis.

2026-09-06
UNH
Company Snapshot

UnitedHealth Group (UNH): What This Company Actually Does

A plain-English read of UnitedHealth's business model — insurance premiums plus the clinics and pharmacies its own members use — built directly from its SEC filings.

2026-09-06